Semax

Semax is a synthetic heptapeptide built by attaching a Pro-Gly-Pro tail to the C-terminus of ACTH(4-7) — the four-residue fragment Met-Glu-His-Phe — yielding the sequence MEHFPGP. The Pro-Gly-Pro extension protects against enzymatic degradation, and follow-up work has shown that the tail itself carries independent neurotrophic activity in rodent stroke models. Mechanistically Semax appears to act through several coupled pathways: in rodents it rapidly elevates brain-derived neurotrophic factor (BDNF) and TrkB receptor expression in the hippocampus, modulates dopaminergic and serotoninergic systems, and influences melanocortin-receptor signaling consistent with its ACTH origin. A representative Western-journal mechanism study reported a 25% rise in striatal 5-HIAA at two hours after Semax administration in rats, with serotonin-metabolite levels reaching 180% of baseline within 1–4 hours; dopamine concentrations were unaltered by Semax alone, but Semax pretreatment substantially enhanced the dopamine response to D-amphetamine ([Eremin et al., *Neurochem Res* 2005, 30:1493–1500](https://doi.org/10.1007/s11064-005-8826-8)). The reading is consistent with Semax acting as a neuromodulatory amplifier rather than a primary releaser.

Semax is the cognitive companion to Selank in the Russian peptide cluster, and the two share an asymmetric evidence base. Semax has been on the Russian List of Vital and Essential Drugs since 1995, with regulatory approval for acute ischemic stroke, transient ischemic attack, post-stroke cognitive rehabilitation, and several cognitive and ophthalmic indications. The Russian clinical literature is substantial — a landmark Gusev / Skvortsova trial in 1997 examined Semax (12–18 mg/day, 5–10 days) added to combined intensive therapy in 30 acute hemispheric ischemic stroke patients versus 80 conventionally treated controls, reporting accelerated regression of motor and general cerebral deficits. Subsequent Russian trials in stroke rehabilitation, optic neuropathy, and cognitive aging have continued to be published in domestic journals, with intermittent indexing in PubMed via translated abstracts. The Western peer-reviewed literature, by contrast, is thin and overwhelmingly mechanistic. Eremin and colleagues' 2005 *Neurochemical Research* paper (the inline citation above) is one of the cleanest Western-indexed mechanism studies; subsequent BDNF-pathway and post-ischemic gene-expression work has appeared in journals like *Genes* and *Neuroscience Letters*, again primarily from Russian-affiliated research groups. The independent Western RCT replication that would translate the Russian stroke-rehabilitation data into a global standard of care has not happened. The honest framing matches Selank's: the evidence base is real but parallel to, not overlapping with, the standards used to approve neurological drugs in the United States or European Union. Most of what is asserted about Semax in English-language wellness writing rests on a Russian clinical literature that has not been independently replicated in Western RCTs and that does not generally meet contemporary FDA or EMA methodological standards. Treat Semax as a plausibly useful peptide with thin Western validation — not as a peer-tested cognitive enhancer or stroke adjunct on the order of established neurology pharmacotherapy.